Key statistics
As of last trade, Invivyd Inc (IVVD:NMQ) traded at 1.67, 261.96% above the 52 week low of 0.46 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.67 |
|---|---|
| High | 1.72 |
| Low | 1.65 |
| Bid | 1.66 |
| Offer | 1.67 |
| Previous close | 1.72 |
| Average volume | 1.38m |
|---|---|
| Shares outstanding | 281.99m |
| Free float | 250.11m |
| P/E (TTM) | -- |
| Market cap | 485.02m USD |
| EPS (TTM) | -0.4736 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 17:54 GMT.
More ▼
- Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
- Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
- Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
- Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
- Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
- Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
- Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
- Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
More ▼
